Literature DB >> 11472356

Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy.

M C Kappers-Klunne1, M B van't Veer.   

Abstract

Patients with chronic immune thrombocytopenic purpura (ITP) who are unresponsive to corticosteroids require splenectomy, but if this fails, treatment is difficult. We tried to induce durable remissions in ITP patients refractory to corticosteroids before or after splenectomy by applying strong immunosuppression with the combination of cyclosporin A (CyA 5 mg/kg/d) and prednisone (0.4 mg/kg/d). Patients were assigned to one of two groups. Group 1, 10 patients refractory to prednisone; and group 2, 10 patients refractory to at least prednisone and splenectomy. Overall response rate was 55% (50% in group 1 and 60% in group 2 patients). Nine of the 10 patients in group 1 finally had a splenectomy because of relapse, insufficient response or toxicity of CyA. Thirty percent of the patients discontinued CyA because of side-effects; hypertension, severe headache and muscle pain being the most frequent encountered. It is concluded that CyA treatment does not avoid, but only postpones, splenectomy in chronic ITP patients who are refractory to corticosteroids. However, CyA can be useful in a subgroup of patients with corticosteroid- and splenectomy-refractory ITP, but treatment toxicity is high.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11472356     DOI: 10.1046/j.1365-2141.2001.02893.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure.

Authors:  Samo Zver; Irena Preloznik Zupan; Peter Cernelc
Journal:  Int J Hematol       Date:  2006-04       Impact factor: 2.490

2.  A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4).

Authors:  Philip Young-Ill Choi; Fernando Roncolato; Xavier Badoux; Sundra Ramanathan; Shir-Jing Ho; Beng H Chong
Journal:  Blood       Date:  2015-05-13       Impact factor: 22.113

Review 3.  Childhood immune thrombocytopenia: Clinical presentation and management.

Authors:  Mohamed El Faki Osman
Journal:  Sudan J Paediatr       Date:  2012

Review 4.  Treatment of immune thrombocytopenic purpura in children : current concepts.

Authors:  Aziza T Shad; Corina E Gonzalez; S G Sandler
Journal:  Paediatr Drugs       Date:  2005       Impact factor: 3.022

Review 5.  Refractory idiopathic immune thrombocytopenic purpura in children: current and future treatment options.

Authors:  Paul Imbach
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

6.  Clinical observation on the treatment of childhood refractory idiopathic thrombocytopenic purpura with Dihuang Zhixue Capsule.

Authors:  Qing-chi Liu; Wei-hai Wu; Da-yong Wu; Xin-wang Feng; Ya-hui Ma; Jian-ying Li; Yu-hui Pang; Shu-hua Song
Journal:  Chin J Integr Med       Date:  2008-08-06       Impact factor: 1.978

7.  Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile.

Authors:  Gregory Cheng
Journal:  Ther Adv Hematol       Date:  2012-06

8.  American Society of Hematology 2019 guidelines for immune thrombocytopenia.

Authors:  Cindy Neunert; Deirdra R Terrell; Donald M Arnold; George Buchanan; Douglas B Cines; Nichola Cooper; Adam Cuker; Jenny M Despotovic; James N George; Rachael F Grace; Thomas Kühne; David J Kuter; Wendy Lim; Keith R McCrae; Barbara Pruitt; Hayley Shimanek; Sara K Vesely
Journal:  Blood Adv       Date:  2019-12-10

Review 9.  Identifying and treating refractory ITP: difficulty in diagnosis and role of combination treatment.

Authors:  Oriana Miltiadous; Ming Hou; James B Bussel
Journal:  Blood       Date:  2020-02-13       Impact factor: 22.113

10.  Long-term management of chronic immune thrombocytopenic purpura in adults.

Authors:  Javier Palau; Isidro Jarque; Miguel A Sanz
Journal:  Int J Gen Med       Date:  2010-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.